BioMarin Pharmaceuticals
BMRN
422 hedge funds and large institutions have $15.4B invested in BioMarin Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 66 funds opening new positions, 175 increasing their positions, 120 reducing their positions, and 32 closing their positions.
106% more first-time investments, than exits
New positions opened: 66 | Existing positions closed: 32
46% more repeat investments, than reductions
Existing positions increased: 175 | Existing positions reduced: 120
24% more capital invested
Capital invested by funds: $12.4B → $15.4B (+$2.94B)
8% more funds holding
Funds holding: 391 → 422 (+31)
2% more call options, than puts
Call options by funds: $127M | Put options by funds: $124M
0% more funds holding in top 10
Funds holding in top 10: 13 → 13 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$411M |
| 2 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$76.8M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$73.6M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$66.1M |
| 5 |
Jennison Associates
New York
|
+$61.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$93.6M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$88.3M |
| 3 |
Sands Capital Management
Arlington,
Virginia
|
-$65.6M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$64.1M |
| 5 |
HM
HealthCor Management
New York
|
-$58.4M |
BMRN Hedge Fund Activity: Q3 2016 in Review
422 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q3 2016, worth a combined $15.4B — up 24% from $12.4B a quarter earlier.
Buyers outnumbered sellers: 66 funds opened new BMRN positions and 32 closed out — a net gain of 34 holders — while 175 added to existing stakes and 120 trimmed.
The largest buyer was Capital Research Global Investors, adding an estimated $411M. The largest seller was Fidelity Investments, cutting an estimated $93.6M.
- 422 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q3 2016, up from 391 in Q2 2016.
- Funds reported $15.4B of BioMarin Pharmaceuticals stock for Q3 2016, up 24% quarter-over-quarter.
- 66 funds opened new BioMarin Pharmaceuticals positions in Q3 2016 and 32 closed out, a net change of +34 holders.
- The largest BioMarin Pharmaceuticals buyer in Q3 2016 was Capital Research Global Investors, an estimated $411M added.
- The largest BioMarin Pharmaceuticals seller in Q3 2016 was Fidelity Investments, an estimated $93.6M sold.
Based on aggregated 13F filings for Q3 2016.